Screening for Interference in Immunoassays
To the Editor: In their report in a recent issue of Clinical Chemistry, Emerson et al. (1 ) screened clinical samples for the presence of interference in four immunoassays. Three different techniques were applied, defining interference as (a) nonlinear assay responses with serial dilution, (b) discrepant assay results after pretreatment with heterophile blocking reagent (HBR), or (c) positive reactions on a mouse-antibody-negative control reaction (Tandem ICON ® ImmunoConcentration hCG). The percentage of interference-positive samples varied significantly by technique, and the authors therefore concluded that prescreening for interfering substances with these assays is not warranted.
False-positive results caused by assay interference could be detrimental if undetected, as shown in the hallmark report by Rotmensch and Cole (2 ) . Interferences have been characterized or labeled as heterophile antibodies, human-anti-mammalian antibodies, human-anti-mouse (mono-clonal) antibodies, rheumatoid factor, and so forth. We would like to advise against the use of serial dilutions to detect these interferences because nonlinear responses between serial dilutions can also originate from other sources, e.g., the heterogeneous nature of the analyte. This lack of parallelism is often encountered for the heterodimer human chorionic gonadotropin (hCG), of which many molecular forms exist. Other well-known causes are the presence of binding proteins or aspecific matrix effects. This is, in our view, the most likely cause of the extremely high prevalence of interference (up to 80%) reported by Emerson et al. (1 ) . Concerning the use of HBR, it would be expected that the blocking of false-positive responses caused by interfering heterophile antibodies would produce lower analyte values. We were surprised to notice mainly higher values for hCG after pretreatment with HBR as demonstrated by the authors, suggesting an unrealistically high prevalence of interference leading to false negatives.
We agree with the authors that screening all clinical samples for all types of possible interferences is not feasible in practice, and we alternatively directed our efforts to devising assays that would be less susceptible to interfering substances (3, 4 ) . Assessment of the presence of interfering substances is done by use of nonfunctional antibody combinations in a sandwich ELISA format that should not give a true signal because it was designed against a nonexistent analyte (so-called nonsense format; see Fig. 1 ). We found that interference was particularly noticeable when we measured lowabundance analytes, necessitating low sample dilution factors. Thus, the impact of assay interference strongly depends on the amount of analyte in the sample.
We established a sandwich immunoassay format that applies avian antibodies in the preanalyte and mammalian antibodies in the postanalyte stage. This has been found to essentially preclude all interference in these assays (3, 4 ) . This effect is obtained because interfering factors that would typically bridge between pre-and postanalyte antibodies in the absence of analyte, leading to false positives, do not bind to avian IgY antibodies. The occurrence of false negatives, induced by shielding of the preanalyte antibodies by the interference, is most likely also prevented by use of this format. Avian antibodies are easily obtained from the eggs of immunized chickens (5, 6 ) .
Thus, the effective use of nonsense formats to assess the presence of interfering substances, and the fact that immunoassays can be devised that are much less susceptible to interference, might be of interest in this matter. In the ELISA for the nonsense analyte [urokinase plasminogen activator-tissue plasminogen activator complex], preanalyte avian or mammalian antibodies were used. For urokinase plasminogen activator, a mammalian preanalyte antibody was used. Samples positive for urokinase plasminogen activator as assessed with mammalian antibodies were also positive for the nonsense analyte. Use of avian antibodies precludes the false-positive results induced by interference attributable to bridging of pre-and postanalyte antibodies in the absence of analyte.
High-Dose Hook Effect in an Immunochromatography-Optical Quantitative Reader Method for Myoglobin
To the Editor: Triaging of patients with chest pain to rule out acute myocardial infarction is important. Myoglobin is thought to be an effective marker for this purpose in the early hours after the onset of symptoms because it is released into the blood shortly after myocardial damage (1-3 ) . The Cardiac Reader (Roche) provides a platform for the quantitative immunologic measurement of whole-blood myoglobin. The measuring range of the Cardiac Reader for myoglobin is 30 -700 g/L, and the upper reference limit is 80 g/L. In a previous study, the within-series CV (the mean value of 20 within-run CVs with 20 instruments) was 5-10% and was almost constant throughout the measuring range (4 ). The assay sys-tem is thought to be suitable for near-patient use because of its easy operation and the short assay time.
We observed two cases whose blood myoglobin concentrations showed falsely low values with this method. Case A was an 84-year-old male in cardiogenic shock attributable to acute myocardial infarction who had a percutaneous transluminal coronary angioplasty immediately after arrival. On day 2 after admission, the blood myoglobin concentration on the Reader was 357 g/L. The cardiac troponin T concentration measured simultaneously was above the upper limit of linearity (Ͼ2.0 g/L). We noted the discrepancy between these results. Because the myoglobin concentration was above the cutoff but not as high as expected, a "hook effect" of myoglobin was suspected. To confirm this suspicion, we diluted the sample 50-and 100-fold with the blood from a healthy individual whose blood myoglobin concentration was Ͻ30 g/L and reassayed the dilutions with the Cardiac Reader. The myoglobin concentrations in these diluted samples were above the upper limit of the system and 376 g/L, respectively ( Table 1 , Case A). These results suggested that the initial result for the undiluted sample was falsely low because of the hook phenomenon at high concentrations of myoglobin.
The second patient was an 88-yearold male who had been on dialysis. He was also diagnosed with an acute myocardial infarction associated with cardiogenic shock. At 5.5 h after his arrival, his blood myoglobin and troponin T were 388 g/L and Ͼ2.0 g/L, respectively. Serum creatine kinase activity was 946.9 kat/L (5670 U/L). We diluted the sample 2-, 4-, 8-, 16-, and 32-fold with the blood from a healthy individual and reassayed the dilutions as for the first case. The myoglobin concentrations in these diluted samples were Ͼ700, 688, 598, 342, and 133 g/L, respectively (Table 1, Case B) . The myoglobin in a serum sample that had been drawn simultaneously was ϳ8000 g/L, as measured on the Elecsys 2010 (Roche Diagnostics). The myo-globin concentration was underestimated in this case as well.
Because there have been no reports of the hook effect for myoglobin on the Cardiac Reader system, we evaluated whether falsely low concentrations below the cutoff would be obtained by preparing blood samples with very high myoglobin concentrations. The myoglobin concentration in a heparin-treated blood sample drawn from a healthy person was Ͻ30 g/L with Cardiac Reader. Myoglobin from human heart (Sigma) was added to the heparinized whole blood to give three specimens with adjusted theoretical concentrations of 115 000, 57 500, and 28 750 g/L. We used two different Cardiac Readers. Instrument A gave values of 435, Ͼ700, and Ͼ700 g/L, whereas instrument B gave values of 526, 617, and Ͼ700 g/L, respectively (Table 1 ). Because the results of the dilution tests in the two cases and in the blood containing the added myoglobin were not coincident with each other, we could not determine the myoglobin concentration at which the hook effect occurs. The reason for this discrepancy is not clear, but one possibility is that it is caused by differences in the antigenicity of the myoglobin in the samples.
Although the hook effect is a common problem in immunoassays, it is observed less frequently in assays using immunochromatography. As with the Cardiac Reader, there have been no reports regarding the frequency of a hook effect. We did not observe falsely low values below the cutoff (80 g/L) in our studies. Other cardiac markers, such as creatine kinase, are probably abnormally high in most cases in which the hook effect of myoglobin occurs; therefore, the risk of making a misdiagnosis is probably limited. However, because blood myoglobin concentrations can become highly increased in some patients, falsely low results below the cutoff are possible with this method, although this was not the case in our study.
In conclusion, users of the Cardiac Reader should recognize the possi-Clinical Chemistry 49, No. 10, 2003
